A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressive disorder (MDD). Essais contrôlé-randomisé en double aveugle évaluant l'impact d'un traitement prophylactique par Galantamine 8mg sur les altérations cognitives pendant une cure d'électroconvulsivothérapie (ECT) chez des patients présentant un épisode dépressif majeur (EDM).

Trial Profile

A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressive disorder (MDD). Essais contrôlé-randomisé en double aveugle évaluant l'impact d'un traitement prophylactique par Galantamine 8mg sur les altérations cognitives pendant une cure d'électroconvulsivothérapie (ECT) chez des patients présentant un épisode dépressif majeur (EDM).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Galantamine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top